ClinicalTrials.gg
Not yet recruitingNCT07546357Updated Apr 22, 2026

AIManage Using an AI-driven CDS and Chatbot

An interventional study of AIManage in Diabetes, Obesity and Medication Side Effects, sponsored by NYU Langone Health. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-22.

Sponsored by NYU Langone Health · Not applicable, Interventional, and Other

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Diabetes Mellitus by NYU Langone Health — 4 open to participants now, 4 under way, none of them phase 3. Diabetes Mellitus · NYU Langone Health.

Planned enrollment
18th of 21
16 · median 200
Started
2026
with 1 other
No phase
19 of 27
4 open now
Registered
27th of 27
by date

Among the 27 studies in Diabetes Mellitus by NYU Langone Health, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2026, is one of 19 with no phase, and was the 27th registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,071 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

4 of the 27 studies in Diabetes Mellitus by NYU Langone Health are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 358 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Diabetes Mellitus by NYU Langone Health, or all of them as a file.
02

Study summary

The objective of this project is to define and test the GenAI-powered Clinical Decision Support (CDS) tool, AIManage, providing a broad range of incretin mimetic medication management services to optimize dose titrations. The study will take place across primary care and obesity medicine clinics at NYUH.

The study is currently conducting formative data collection for tool refinement (Phase 1). Once completed, a cluster randomized controlled trial of the AIManage tool will be undertaken (Phase 2).

03

Conditions studied

  • Diabetes
  • Obesity
  • Medication Side Effects

Keywords

  • GLP-1
  • Incretin mimetic
  • medication management
  • side effect management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Provider Eligibility Criteria (Phase 1)

  • Primary or bariatric care provider (MD/DO, NP) practicing at the participating NYULH clinics,
  • Provide care to at least 5 patients prescribed an IMM.

Patient Eligibility Criteria (Phase 1)

  • (Phase 1) Currently taking an IMM or have taken an IMM in the past 6 months;
  • Fluency in English or Spanish;
  • Be willing to send/receive text messages; and
  • Be > 18 years of age.

Exclusion criteria

Exclusion Criteria:

Provider Exclusion Criteria (Phase 1) • Refuse to participate

Patient Exclusion Criteria (Phase 1)

  • Refuse or are unable to provide ;
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Providers (Phase 1)

    Providers prescribing IMM for at least 5 adult patients in primary care and obesity medicine clinics.

    Other: AIManage

  • Experimental
    Patients (Phase 1)

    Adult patients prescribed an IMM in the past 6 months.

    Other: AIManage

Interventions

  • OtherAIManage

    GenAI-powered CDS tool that provides a range of IMM management services, such as personalized guidance for patients on side effects management and clinical advisement to optimize dose titrations.

06

What researchers measure

Primary outcomes

  1. Percentage of Patients who Complete Qualitative Measure - Perceived Usefulness

    In Phase 1, qualitative data regarding perceived usefulness will be collected.

    Time frame: Day 1 (60 minutes)

  2. Percentage of Patients who Complete Qualitative Measure - Perceived Usability

    In Phase 1, qualitative data regarding perceived usability will be collected.

    Time frame: Day 1 (60 minutes)

  3. Percentage of Patients who Complete Qualitative Measure - Perceived Use Challenges

    In Phase 1, qualitative data regarding perceived use challenges will be collected.

    Time frame: Day 1 (60 minutes)

  4. Percentage of Patients who Complete Qualitative Measure - Perceived Value

    In Phase 1, qualitative data regarding perceived value will be collected.

    Time frame: Day 1 (60 minutes)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Elizabeth.Stevens@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research

Access criteria: The investigator who proposed to use the data will be granted access upon reasonable request. Requests should be directed to Elizabeth.Stevens@nyulangone.org. To gain access, data requestors will need to sign a data access agreement. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's DSSB.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Mar 2028, 21 months later.

Of 1,590 non-industry interventional studies with no phase under Diabetes Mellitus, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 21 months is close to that.

Counting every sponsor, half of 1,750 studies reached it within 21 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2026
First posted
Apr 22, 2026
StartEst.
Jun 1, 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Mar 30, 2029
Last update
Apr 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07546357
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Apr 22, 2026
Start date
Jun 1, 2026 (estimated)
Primary completion
Mar 30, 2028 (estimated)
Completion
Mar 30, 2029 (estimated)
Last update
Apr 22, 2026

Study contacts

Elizabeth Stevens, PhD, MPH
Contact
Elizabeth.Stevens@nyulangone.org
646-501-2558
Elizabeth Stevens, PhD, MPH
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion